Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients-Reference-Cited by-同舟云学术

Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients

Published:2023-07 Issue: Volume:163 Page:114851
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Kwapisz Dorota,Bogusławska Joanna

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference51 articles.

1. Imbalanced host response to SARS-CoV-2 drives development of COVID-19;Blanco-Melo;Cell,2020

2. W.H.O. Coronavirus Disease (COVID-19). Available online: 〈https://www.who.int/emergencies/diseases/novel-coronavirus-2019〉. Accessed 25 February 2023.

3. COVID-19 outbreak: an overview;Ciotti;Chemotherapy,2020

4. Intravenous immunoglobulin treatment for patients with severe COVID-19: A retrospective multicentre study;Liu;Clin. Microbiol Infect.,2021

5. Update on the use of immunoglobulin in human disease: a review of evidence;Perez;J. Allergy Clin. Immunol.,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Moderate-to-Severe Hospitalized COVID-19 Patients: A Randomized, Open-Label Parallel-Group Study;Canadian Journal of Infectious Diseases and Medical Microbiology;2024-05-21

2. Intravenous immunoglobulins for the treatment of prolonged COVID-19 in immunocompromised patients: a brief report;Frontiers in Immunology;2024-04-19

3. Intravenous immunoglobulin as a potential treatment for long COVID;Expert Opinion on Biological Therapy;2023-12-02

4. Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy;International Immunopharmacology;2023-12

5. Evaluation of Complement Level, Serum Electrophoretic Panel, and Anti-glomerular Basement Membrane in Coronavirus Disease 2019: Focus on Likelihood of Hypersensitivity Type III;International Journal of Enteric Pathogens;2023-11-30